Change s of haemagglutination inhibitionan tibody level within one month after in fluenza A (H1N 1) vaccination
10.3760/cma.j.issn.0254-5101.2013.10.006
- VernacularTitle:不同年龄人群接种甲型 H1 N1流感疫苗后1个月内抗体水平的变化
- Author:
Qing-hua CHEN
;
Guo-ming ZHANG
;
Yan LI
;
Fang-jun LI
;
Qiu-feng TU
;
Ping YUAN
;
Fu WANG
;
Qi-you XIAO
;
Hua-qing WANG
;
Yun-tao NG ZHA
- Publication Type:Journal Article
- Keywords:
Pandemic A/H1N1 influenza vaccine;
Hemagglutination inhibition test;
Changes of HI antibody level
- From:
Chinese Journal of Microbiology and Immunology
2013;(10):744-749
- CountryChina
- Language:Chinese
-
Abstract:
Objective To find the changes of haemagglutination inhibition ( HI ) antibody level against A/California/07/2009 (H1N1) within one month after pandemic A/H1N1 influenza vaccine (A/H1N1InfV) vaccination, and to provide data for drawing up immunization protocols against novel influenza . Methods The HI antibodies against A/California/07/2009 (H1N1) in sera from the inoculated subjects were tested by HI test .The geometric mean titer ( GMT) , geometric mean increase ( GMI) , seroconversion (SC) rate, seroprotection (SP) rate of HI antibodies were compared among the sera collected on day 3, 7, 14, 30 post vaccination .Results 961 participants were injected with A/H1N1InfV.In subjects aged 3 to 11 years, the antibody level peaked on day 14 post vaccination, but neither on day 14 nor on day 30, the lower bound of the two -sided 95%CI for the SP rate could fulfill the criteria of the FDA for influenza vac-cine.In subjects aged 12 to 60 years, the antibody level peaked on day 14 post vaccination and the SC rate , SP rate and GMI fulfilled the criteria of the European Medicines Agency ( EMEA) and the FDA for influenza vaccine. In subjects aged more than 60 years, the antibody level peaked on day 30 post vaccination , and the SC rate, SP rate and GMI on day 30 fulfilled the criteria of the EMEA and the FDA .Conclusion One dose A/H1N1InfV vaccination was able to induce enough protection on day 14 for subjects aged 12 to 60 years, on day 30 for subjects aged more than 60 years;however , for subjects aged 3 to 11 years who were antibody-negative at baseline , the lower bound of the two-sided 95%CI for the SP rate on day 14 and day 30 couldn′t fulfill the criteria of the FDA for influenza vaccine .
